SPOTLIGHT: ARYx slashes IPO price
ARYx Therapeutics (a 2004 Fierce 15 company) raised $50 million in its IPO after slashing its price from a forecasted $14 to $16 a share down to $10. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
